Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: PeterR1700 who wrote (1790)	12/9/1998 9:52:00 AM
From: Walter Morton	Read Replies (1) \| Respond to of 2742

Well, I think CIST lacks the desire and ability to market its product and grow its company profitably. So, I have suggested that CIST grow, improve its marketing skills and profitability by using its cash to acquire a company that has the skills that CIST currently seems to lack. HMGM seems to be a very good match relative to price: $12 in sales, profitable, growing, and only $.8125/share yesterday. ENDG is too expensive. BIOI is not profitable.